Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

ALDER BIOPHARM Form 4 May 15, 2014	MACEUTICALS I	NC						
May 13, 2014OMBFORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549OMBCheck this box if no longer subject to Section 16. Form 4 or Form 5 								
(Print or Type Responses 1. Name and Address of SIEGALL CLAY B	2. Issuer Name and Symbol ALDER BIOPHA INC [ALDR]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First C/O ALDER BIOPHARMACEU' INC., 11804 NORT PARKWAY SOUT	TICALS, H CREEK	3. Date of Earliest Tr. (Month/Day/Year) 05/13/2014	ansaction		X Director Officer (give below)		o Owner er (specify	
(Street) 4. If Amendment, D Filed(Month/Day/Yea BOTHELL, WA 98011) Applicable Line) _X_ Form filed by			oint/Group Filing(Check One Reporting Person More than One Reporting		
(City) (State	e) (Zip)	Table I - Non-D	erivative Se	curities Acq	uired, Disposed of	f, or Beneficial	ly Owned	
	action Date 2A. Deer /Day/Year) Executio any (Month/I		4. Securitie on(A) or Disp (D) (Instr. 3, 4 Amount	osed of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common 05/13/ Stock	2014	С		A (<u>1</u>)	24,444	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. P Deri Secu (Ins
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Series B Preferred Stock	<u>(1)</u>	05/13/2014		С		11,188	<u>(1)</u>	<u>(1)</u>	Common Stock	11,188	\$
Series D Preferred Stock	(1)	05/13/2014		С		13,256	<u>(1)</u>	(1)	Common Stock	13,256	\$

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
SIEGALL CLAY B C/O ALDER BIOPHARMACEUTICALS, INC. 11804 NORTH CREEK PARKWAY SOUTH BOTHELL, WA 98011	Х				
Signatures					

/s/ Clay Siegall 05/13/2014 <u>**</u>Signature of Date Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The preferred stock converted into common stock on a 1-for-1 basis upon the closing of the issuer's initial public offering and had no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.